Form 4 for PAHC PHIBRO ANIMAL HEALTH CORP
Accepted 2025-10-21 00:00:00 ET · period of report 2025-10-17 · accession 0001104659-25-101314 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2025-10-21 | 2025-10-17+ | PAHC | BENDHEIM JACK | Pres, CEO, Dir, 10% | S - Sale | $40.37 | -16.8K | 40.0K | -30% | -$677.1K |
| DI | 2025-10-21 | 2025-10-21 | PAHC | BENDHEIM JACK | Pres, CEO, Dir, 10% | C - Cnv Deriv | $0.00 | +50.0K | 73.9K | +209% | $0 |
| DI | 2025-10-21 | 2025-10-21 | PAHC | BENDHEIM JACK | Pres, CEO, Dir, 10% | C - Cnv Deriv | $0.00 | -50.0K | 20.09M | -0.2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-10-20 | S | D | 16,075 | $40.38 | 23,899 | I See | — | — | (F4) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.59. (F3) The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 2 | Common | Class A Common Stock | 2025-10-21 | C | A | 50,000 | $0.00 | 73,899 | I See | — | — | (F3) The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 3 | Common | Class A Common Stock | 2025-10-17 | S | D | 700 | $40.03 | 39,974 | I See | — | — | (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.07. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F3) The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 4 | Derivative | Class B Common Stock | 2025-10-21 | C | D | 50,000 | $0.00 | 20,086,034 | I See | $0.00 · — to — | 50,000 Class A Common Stock | (F3) The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F5) Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date. |